AR097204A1 - Métodos de tratamiento de tumores sólidos - Google Patents

Métodos de tratamiento de tumores sólidos

Info

Publication number
AR097204A1
AR097204A1 ARP140102910A ARP140102910A AR097204A1 AR 097204 A1 AR097204 A1 AR 097204A1 AR P140102910 A ARP140102910 A AR P140102910A AR P140102910 A ARP140102910 A AR P140102910A AR 097204 A1 AR097204 A1 AR 097204A1
Authority
AR
Argentina
Prior art keywords
solid tumors
treatment methods
composition
pci
tumors treatment
Prior art date
Application number
ARP140102910A
Other languages
English (en)
Spanish (es)
Inventor
Balasubramanian Sriram
Original Assignee
Pharmacyclics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacyclics Inc filed Critical Pharmacyclics Inc
Publication of AR097204A1 publication Critical patent/AR097204A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP140102910A 2013-08-02 2014-08-01 Métodos de tratamiento de tumores sólidos AR097204A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361861853P 2013-08-02 2013-08-02

Publications (1)

Publication Number Publication Date
AR097204A1 true AR097204A1 (es) 2016-02-24

Family

ID=52428222

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140102910A AR097204A1 (es) 2013-08-02 2014-08-01 Métodos de tratamiento de tumores sólidos

Country Status (7)

Country Link
US (1) US9421208B2 (OSRAM)
EP (1) EP3027192A4 (OSRAM)
JP (1) JP6800750B2 (OSRAM)
AR (1) AR097204A1 (OSRAM)
CA (1) CA2919996A1 (OSRAM)
TW (1) TWI649081B (OSRAM)
WO (1) WO2015017812A1 (OSRAM)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2201840E (pt) 2006-09-22 2012-02-14 Pharmacyclics Inc Inibidores da tirosina quinase de bruton
US8809273B2 (en) 2007-03-28 2014-08-19 Pharmacyclics, Inc. Inhibitors of Bruton's tyrosine kinase
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
TWI458721B (zh) 2008-06-27 2014-11-01 Celgene Avilomics Res Inc 雜芳基化合物及其用途
AU2009270856B2 (en) 2008-07-16 2013-07-25 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors
US8603521B2 (en) 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
KR101705158B1 (ko) 2009-05-05 2017-02-09 다나-파버 캔서 인스티튜트 인크. Ｅｇｆｒ 억제제 및 질환 치료방법
EA201890869A3 (ru) 2010-06-03 2019-03-29 Фармасайкликс, Инк. Применение ингибиторов тирозинкиназы брутона (btk)
CN103081471B (zh) * 2010-07-15 2017-06-06 夏普株式会社 帧内预测模式估计装置、编码装置、以及解码装置
RU2013109393A (ru) 2010-08-10 2014-09-20 Сэлджин Авиаломикс Ресеарч, Инк. Безилатная соль ингибитора втк
EP2635285B1 (en) 2010-11-01 2017-05-03 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
CA2815858C (en) 2010-11-01 2018-10-16 Celgene Avilomics Research, Inc. Heterocyclic compounds and uses thereof
EP2637502B1 (en) 2010-11-10 2018-01-10 Celgene CAR LLC Mutant-selective egfr inhibitors and uses thereof
AU2012283775A1 (en) 2011-07-13 2014-01-23 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
EP2755648B1 (en) 2011-09-13 2017-03-08 Pharmacyclics LLC Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
CA2853498A1 (en) 2011-10-28 2013-05-02 Celgene Avilomics Research, Inc. Methods of treating a bruton's tyrosine kinase disease or disorder
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
CA3218491A1 (en) 2012-06-04 2013-12-12 Pharmacyclics Llc Crystalline forms of a bruton's tyrosine kinase inhibitor
WO2014018567A1 (en) 2012-07-24 2014-01-30 Pharmacyclics, Inc. Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
JP2015537033A (ja) 2012-11-15 2015-12-24 ファーマサイクリックス，インク． キナーゼ阻害剤としてのピロロピリミジン化合物
WO2014100748A1 (en) 2012-12-21 2014-06-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
EP2953457B1 (en) 2013-02-08 2020-04-08 Celgene CAR LLC Erk inhibitors and uses thereof
EP3033079B1 (en) 2013-08-12 2018-10-31 Pharmacyclics LLC Methods for the treatment of her2 amplified cancer
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9624224B2 (en) 2013-09-30 2017-04-18 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
CA2942528A1 (en) 2014-03-20 2015-09-24 Pharmacyclics Inc. Phospholipase c gamma 2 and resistance associated mutations
WO2015187848A1 (en) * 2014-06-04 2015-12-10 Sampath Deepa Hdac inhibitor and btk inhibitor combinations
WO2016019233A1 (en) 2014-08-01 2016-02-04 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
MX2017001671A (es) 2014-08-07 2017-07-04 Pharmacyclics Llc Formulaciones novedosas de un inhibidor de la tirosina cinasa de bruton.
EP3179858B1 (en) 2014-08-13 2019-05-15 Celgene Car Llc Forms and compositions of an erk inhibitor
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
JP6823587B2 (ja) 2015-04-13 2021-02-03 第一三共株式会社 Ｍｄｍ２阻害剤とｂｔｋ阻害剤との併用治療法
CN105753863B (zh) * 2015-09-11 2018-07-31 东莞市真兴贝特医药技术有限公司 氧代二氢咪唑并吡啶类化合物及其应用
GB201703876D0 (en) * 2017-03-10 2017-04-26 Berlin-Chemie Ag Pharmaceutical combinations
CN116057045A (zh) 2020-06-05 2023-05-02 金耐特生物制药公司 成纤维细胞生长因子受体激酶抑制剂
USD910604S1 (en) * 2020-07-22 2021-02-16 Crown Tech Llc Microphone isolation shield
USD905022S1 (en) * 2020-07-22 2020-12-15 Crown Tech Llc Microphone isolation shield

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE794063A (fr) 1972-01-17 1973-07-16 Henkel & Cie Gmbh Anti-inflammatoires pour compositions cosmetiques
EP0084236A3 (en) 1981-12-22 1983-08-03 Fbc Limited Fungicidal heterocyclic compounds and compositions containing them
EP0394440B1 (en) 1987-10-20 1994-05-11 Otsuka Pharmaceutical Co., Ltd. Phenylcarboxylic acid derivatives
JPH03215470A (ja) 1990-01-22 1991-09-20 Suntory Ltd プロピオン酸アミド誘導体，その製造法及びそれを有効成分として含有する除草剤
DE4124345A1 (de) 1991-07-23 1993-01-28 Gruenenthal Gmbh Substituierte 3,4-dihydronaphthaline, diese verbindungen enthaltende arzneimittel und verfahren zur herstellung dieser verbindungen und arzneimittel
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
DE4327365A1 (de) 1993-08-14 1995-02-16 Boehringer Mannheim Gmbh Verwendung von Phenolen und Phenolderivaten als Arzneimittel mit fibrinogensenkender Wirkung
US6326469B1 (en) 1994-04-22 2001-12-04 Sugen, Inc. Megakaryocytic protein tyrosine kinases
US5593997A (en) 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
CH690773A5 (de) 1996-02-01 2001-01-15 Novartis Ag Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
US5958957A (en) 1996-04-19 1999-09-28 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
ATE269295T1 (de) 1998-04-17 2004-07-15 Parker Hughes Inst Btk inhibitoren und verfahren zur identifizierung und verwendung
US6303652B1 (en) 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
US6335155B1 (en) 1998-06-26 2002-01-01 Sunesis Pharmaceuticals, Inc. Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
US6998233B2 (en) 1998-06-26 2006-02-14 Sunesis Pharmaceuticals, Inc. Methods for ligand discovery
US20050287596A9 (en) 1998-06-26 2005-12-29 Braisted Andrew C Novel ligands and libraries of ligands
US6211197B1 (en) 1998-10-07 2001-04-03 Merck Frosst Canada & Co. Prostaglandin receptor ligands
US6306897B1 (en) 1999-03-19 2001-10-23 Parker Hughes Institute Calanolides for inhibiting BTK
AU6936500A (en) 1999-08-24 2001-03-19 Regents Of The University Of California, The Non-quinoline inhibitors of malaria parasites
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
DE60004685T2 (de) 1999-09-17 2004-07-29 Abbott Gmbh & Co. Kg Pyrazolopyrimidine als arzneimittel
US6506769B2 (en) 1999-10-06 2003-01-14 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
EP1222187B1 (en) 1999-10-06 2004-09-22 Boehringer Ingelheim Pharmaceuticals Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
DK1233958T3 (da) 1999-11-23 2011-10-17 Methylgene Inc Hæmmere af histondeacetylase
CA2390857A1 (en) 1999-11-30 2001-06-14 Fatih M. Uckun Inhibitors of collagen-induced platelet aggregation
CA2394650A1 (en) 1999-12-17 2001-06-21 Chi B. Vu Novel heterocycles
GB0005345D0 (en) 2000-03-06 2000-04-26 Mathilda & Terence Kennedy Ins Methods of treating sepsis septic shock and inflammation
GB0023983D0 (en) 2000-09-29 2000-11-15 Prolifix Ltd Therapeutic compounds
EP2292593A3 (en) 2000-09-29 2011-05-25 TopoTarget UK Limited Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
HU230302B1 (hu) 2000-10-20 2015-12-28 Eisai R&D Management Co., Ltd. Nitrogéntartalmú aromás származékok és ezeket tartalmazó gyógyászati készítmények
US20030040461A1 (en) 2000-10-23 2003-02-27 Mcatee C. Patrick Modulators of Bruton'sTyrosine Kinase and Bruton's Tyrosine Kinase intermediates and methods for their identification and use in the treatment and prevention of osteoporosis and related diseases states
AU2002232492A1 (en) 2000-12-06 2002-06-18 Pharmacia Corporation Rapidly dispersing pharmaceutical composition comprising effervescent agents
MXPA03008560A (es) 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
US8306897B2 (en) 2001-05-04 2012-11-06 Stockshield, Inc. Method and system for insuring against investment loss
US20030114467A1 (en) 2001-06-21 2003-06-19 Shakespeare William C. Novel pyrazolo- and pyrrolo-pyrimidines and uses thereof
EP1418917A1 (en) 2001-08-10 2004-05-19 Novartis AG Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia
WO2003016338A1 (en) 2001-08-15 2003-02-27 Parker Hughes Institute Crystal structure of the btk kinase domain
NZ532579A (en) 2001-11-21 2006-11-30 Sunesis Pharmaceuticals Inc Methods for ligand discovery based on tethering process
AU2003211362A1 (en) 2002-02-21 2003-09-09 Osaka Industrial Promotion Organization N-hydroxycarboxamide derivative
US20040132825A1 (en) 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
US20050084905A1 (en) 2002-03-21 2005-04-21 Prescott John C. Identification of kinase inhibitors
GB2388594A (en) 2002-05-16 2003-11-19 Bayer Ag Imidazo-triazine PDE 4 inhibitors
JP2005539001A (ja) 2002-08-02 2005-12-22 アージェンタ・ディスカバリー・リミテッド ヒストンデアセチラーゼインヒビターとしての置換チエニルヒドロキサム酸
WO2004014905A1 (en) 2002-08-08 2004-02-19 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted benzimidazole compounds
GB0303910D0 (en) 2003-02-20 2003-03-26 Merck Sharp & Dohme Therapeutic agents
US7381825B2 (en) 2003-03-17 2008-06-03 Takeda San Diego, Inc. Histone deacetylase inhibitors
ES2328819T3 (es) 2003-04-07 2009-11-18 Pharmacyclics, Inc. Hidroxamatos como agentes terapeuticos.
US7687506B2 (en) 2003-04-11 2010-03-30 The Regents Of The University Of California Selective serine/threonine kinase inhibitors
WO2004100868A2 (en) 2003-04-23 2004-11-25 Abbott Laboratories Method of treating transplant rejection
EP1473039A1 (en) 2003-05-02 2004-11-03 Centre National De La Recherche Scientifique (Cnrs) Use of inhibitors and antisense oligonucleotides of BTK for the treatment of proliferative mastocytosis
WO2005014599A1 (en) 2003-06-04 2005-02-17 Cellular Genomics, Inc. Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds
WO2005005429A1 (en) 2003-06-30 2005-01-20 Cellular Genomics, Inc. Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds
US8131475B2 (en) 2003-09-03 2012-03-06 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods for identifying, diagnosing, and predicting survival of lymphomas
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
WO2005060956A1 (en) 2003-12-12 2005-07-07 University Of Maryland, Baltimore IMMUNOMODULATORY COMPOUNDS THAT TARGET AND INHIBIT THE pY+3 BINDING SITE OF TYROSENE KINASE p56 LCK SH2 DOMAIN
BRPI0418031A (pt) 2003-12-22 2007-04-17 Gilead Sciences Inc inibidores de quinase fosfonato-substituìdos
EP1716151A1 (en) 2004-01-26 2006-11-02 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
EP1730148A4 (en) 2004-02-03 2009-08-19 Abbott Lab USE OF AMINOBENZOXAZOLES AS THERAPEUTIC AGENTS
US7368476B2 (en) 2004-04-07 2008-05-06 Pharmacyclics, Inc. Hydroxamates as therapeutic agents
EP1761281A1 (en) 2004-06-04 2007-03-14 Pfizer Products Incorporated Method for treating abnormal cell growth
JP2008514635A (ja) 2004-09-27 2008-05-08 コーザン バイオサイエンシス インコーポレイテッド 特異的キナーゼ阻害剤
EP1802602A1 (en) 2004-09-28 2007-07-04 Janssen Pharmaceutica N.V. Substituted dipiperdine ccr2 antagonists
AU2005317047A1 (en) 2004-11-05 2006-06-22 Cephalon, Inc. Cancer treatments
SG159549A1 (en) 2004-11-10 2010-03-30 Cgi Pharmaceuticals Inc Imidazo[1,2-a] pyrazin-8-ylamines useful as modulators of kinase activity
GB0425035D0 (en) 2004-11-12 2004-12-15 Novartis Ag Organic compounds
BRPI0608252A2 (pt) 2005-03-10 2010-04-06 Cgi Pharmaceuticals Inc entidades quìmicas, composições farmacêuticas compreendendo as mesmas, métodos utilizando as referidas entidades quìmicas e uso das referidas entidades quìmicas
EP1891066B1 (en) 2005-05-13 2010-12-22 Irm, Llc Compounds and compositions as protein kinase inhibitors
UA95244C2 (ru) 2005-06-22 2011-07-25 Плексикон, Инк. Соединения и способ модулирования активности киназ, и показания для их применения
CA2629314A1 (en) 2005-11-12 2007-05-24 Boehringer Ingelheim International Gmbh Tec kinase inhibitors
US7933820B2 (en) 2006-01-13 2011-04-26 Data Trace Information Services, Llc Method and apparatus for compiling data from property title documents
CN101421269A (zh) 2006-01-13 2009-04-29 环状药物公司 酪氨酸激酶抑制剂及其用途
US20090317836A1 (en) 2006-01-30 2009-12-24 The Scripps Research Institute Methods for Detection of Circulating Tumor Cells and Methods of Diagnosis of Cancer in Mammalian Subject
EP2591775A1 (en) * 2006-04-05 2013-05-15 Novartis AG Combinations comprising mtor inhibitors for treating cancer
US8604031B2 (en) 2006-05-18 2013-12-10 Mannkind Corporation Intracellular kinase inhibitors
US20090312284A1 (en) 2006-09-15 2009-12-17 Janine Arts Histone deacetylase inhibitors with combined activity on class-i and class-iib histone deacetylases in combination with proteasome inhibitors
PT2201840E (pt) 2006-09-22 2012-02-14 Pharmacyclics Inc Inibidores da tirosina quinase de bruton
EP2089391B1 (en) 2006-11-03 2013-01-16 Pharmacyclics, Inc. Bruton's tyrosine kinase activity probe and method of using
EP2626067A1 (en) 2006-12-26 2013-08-14 Pharmacyclics, Inc. Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy
US7838234B2 (en) 2007-01-30 2010-11-23 Pharmacyclics, Inc. Methods for determining cancer resistance to histone deacetylase inhibitors
NL2000640C2 (nl) 2007-03-05 2008-09-08 Stichting Wetsus Ct Of Excelle Werkwijze en systeem voor het zuiveren van een vloeistof.
US8809273B2 (en) 2007-03-28 2014-08-19 Pharmacyclics, Inc. Inhibitors of Bruton's tyrosine kinase
EA017865B1 (ru) 2007-03-28 2013-03-29 Фармасайкликс, Инк. Ингибиторы тирозинкиназы брутона
US20120065201A1 (en) 2007-03-28 2012-03-15 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
CA2702674C (en) 2007-10-19 2016-05-03 Avila Therapeutics, Inc. Heteroaryl compounds and uses thereof
US7989465B2 (en) 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
CA2701275C (en) 2007-10-23 2016-06-21 F. Hoffmann-La Roche Ag Kinase inhibitors
US8426441B2 (en) 2007-12-14 2013-04-23 Roche Palo Alto Llc Inhibitors of bruton's tyrosine kinase
EP2110377A1 (en) 2008-04-15 2009-10-21 DAC S.r.l. Spirocyclic derivatives as histone deacetylase inhibitors
TWI458721B (zh) 2008-06-27 2014-11-01 Celgene Avilomics Res Inc 雜芳基化合物及其用途
AU2009270856B2 (en) * 2008-07-16 2013-07-25 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors
US8603521B2 (en) 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
EP2424368B1 (en) 2009-04-29 2014-12-31 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds
EP2478361A4 (en) 2009-09-16 2014-05-21 Celgene Avilomics Res Inc CONJUGATES AND INHIBITORS OF PROTEIN KINASE
US7741330B1 (en) 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
US20120071497A1 (en) 2010-06-03 2012-03-22 Pharmacyclics, Inc. Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
EA201890869A3 (ru) 2010-06-03 2019-03-29 Фармасайкликс, Инк. Применение ингибиторов тирозинкиназы брутона (btk)
LT2585470T (lt) 2010-06-23 2017-04-10 Hanmi Science Co., Ltd. Nauji kondensuoti pirimidino dariniai tirozino kinazės aktyvumo slopinimui
RU2013109393A (ru) 2010-08-10 2014-09-20 Сэлджин Авиаломикс Ресеарч, Инк. Безилатная соль ингибитора втк
AU2012275275A1 (en) * 2011-06-28 2014-01-23 Pharmacyclics Llc Methods and compositions for inhibition of bone resorption
UY34295A (es) 2011-09-08 2013-04-30 Servier Lab Nuevo esquema de administración de la n-hidroxi -4- {2-[3- (n,ndimetilaminometil)benzofuran -2- ilcarbonilamino]etoxi}benzamida
US8501724B1 (en) 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
CA2890111A1 (en) * 2012-11-02 2014-05-08 Pharmacyclics, Inc. Tec family kinase inhibitor adjuvant therapy
BR112015025711A8 (pt) * 2013-04-08 2019-12-17 Janssen Pharmaceutica Nv uso de ibrutinibe e coposição farmacêutica compreendendo ibrutinibe e um agente anticâncer
TWI660739B (zh) 2013-10-25 2019-06-01 製藥公司 使用布魯頓氏酪胺酸激酶抑制劑之治療及免疫療法
CN103923084B (zh) 2014-01-29 2016-08-17 苏州晶云药物科技有限公司 几种晶型及其制备方法

Also Published As

Publication number Publication date
TWI649081B (zh) 2019-02-01
CA2919996A1 (en) 2015-02-05
JP2016529245A (ja) 2016-09-23
WO2015017812A1 (en) 2015-02-05
US9421208B2 (en) 2016-08-23
US20150038518A1 (en) 2015-02-05
JP6800750B2 (ja) 2020-12-16
TW201601727A (zh) 2016-01-16
EP3027192A1 (en) 2016-06-08
EP3027192A4 (en) 2017-03-22

Similar Documents

Publication Publication Date Title
AR097204A1 (es) Métodos de tratamiento de tumores sólidos
AR112074A2 (es) Derivados de 2-carboxamida-cicloamino-urea como inhibidores de pi-3
EA201100358A1 (ru) Дабигатран для чрескожной хирургической катетеризации сердца
CY1121421T1 (el) Φαρμακοτεχνικες μορφες
CO6382125A2 (es) Inhibidores de proteína quinasa
AR082091A1 (es) Composiciones farmaceuticas que comprenden pioglitazona y linagliptina y procedimiento de preparacion
CL2013001381A1 (es) Compuestos derivados de hidroxi-amida pirimidina, inhibidores de la proteina deacetilasa hdac6; composicion farmaceutica; combinación farmaceutica; metodos de uso para el tratamiento de una enfermedad proliferativa o cancer; un kit
GEP20125624B (en) Pyridazine derivatives as smo inhibitors
CY2016015I2 (el) Αζετιδινες ως αναστολεις μεκ για τη θεραπευτικη αγωγη πολλαπλασιαστικων ασθενειων
HUE047841T2 (hu) L-dopa, dopa dekarboxiláz inhibitorok, katekol-o-metil transzferáz inhibitorok folyamatos adagolására szolgáló készítmények
ECSP11011151A (es) Compuestos purina
EA201071099A1 (ru) СОЛЕВЫЕ ФОРМЫ ИНГИБИТОРА mTOR
NI201200072A (es) Métodos y composiciones para tratar cáncer
MX346186B (es) Inhibidores de proteina cinasas.
NZ621221A (en) Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
MX378867B (es) Inhibidores de la nep para el tratamiento de enfermedades caracterizadas por el ensanchamiento o remodelacion auricular.
AR080491A1 (es) Formulaciones orales y sales lipofilicas de metilnaltrexona
NO20080220L (no) Formuleringer med hoy medikament belastning og doseringsformer
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
EA201100921A1 (ru) Соединения, фармацевтические композиции и способы их применения при лечении нарушений обмена веществ
EA201390428A1 (ru) Композиции и способы лечения легочной гипертензии
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
EA201201202A1 (ru) Пероральная фармацевтическая композиция, содержащая этексилат дабигатрана
EA200802324A1 (ru) Новая форма введения рацекадотрила
EA201100255A1 (ru) 5-алкинилпиримидины

Legal Events

Date Code Title Description
FB Suspension of granting procedure